Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT05007769
Title Ramucirumab, Atezolizumab and N-803 After Progression on Any Immune Checkpoint Blocker in NSCLC (RAN)
Recruitment Withdrawn
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors Washington University School of Medicine
Indications

lung non-small cell carcinoma

Therapies

ALT-803 + Atezolizumab + Ramucirumab

Age Groups: adult | senior
Covered Countries

Additional content available in CKB BOOST